It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
HOME > BUSINESS
BUSINESS
- Boehringer’s Ofev Gets Orphan Status for ILD in Systemic Sclerosis
March 27, 2019
- Novartis Snags Japan Approval for CAR-T Therapy Kymriah
March 26, 2019
- Novartis to Tap Disease Registry for Kymriah’s All-Case PMS: Exec
March 26, 2019
- SanBio to Move Ahead with SB623 Development in Stroke after PII Miss: President
March 26, 2019
- Avanir’s Alzheimer’s Agitation Drug Hits Primary Goal in PIII
March 26, 2019
- AstraZeneca Grabs All Global Fasenra Rights in Expanded Pact with Kyowa Kirin
March 26, 2019
- Vimpat IV Version Hits Japan Market: UCB, Daiichi Sankyo
March 26, 2019
- Ono Chief Recounts Long and Winding Road of Opdivo Development, Thanks Kyoto Univ. Professor
March 25, 2019
- JCR Files Temcell for Epidermolysis Bullosa
March 25, 2019
- Japan Biosimilar Market Could Grow Like in Europe If Incentives Improved: Sandoz Japan Chief
March 25, 2019
- Eisai Going Ahead with Global PIII for BAN2401 despite Aducanumab Setback
March 25, 2019
- Analyst Says Drug Makers Can’t Recoup Investment in Overcompetitive Oncology Arena
March 22, 2019
- Biogen/Eisai’s Aducanumab Fails, Dashing Hopes in Alzheimer’s Field
March 22, 2019
- J-TEC Submits Japan’s First Regenerative Medicine Product in Ophthalmology Field
March 22, 2019
- Mitsubishi Tanabe Sets Up Sales Subsidiary in Malaysia for Independent Marketing
March 22, 2019
- Takeda Taps Neuro-Psychiatric Expert Kajii as T-CiRA Chief
March 22, 2019
- Nippon Shinyaku Licenses Dravet Syndrome Treatment from Zogenix
March 22, 2019
- Chugai, SRL Link Up for Cancer Gene Mutation Tests
March 22, 2019
- Medipal Holdings Invests in Belgium’s Cell Therapy Developer
March 22, 2019
- Gilead Set to Duplicate Biktarvy Success in Japan with New Stand-Alone HIV Sales Force
March 20, 2019
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…